Analysis of DNM2, EPN2 and EXOC4 relative gene expression levels in peripheral blood from Parkinson’s disease patients

Semenova E.I.; Rudenok M.M.; Alieva A.Kh.; Karabanov A.V.; Illarioshkin S.N.; Slominsky P.A.; Shadrina M.I.

doi:https://doi.org/10.17116/molgen20213903125

Semenova E.I.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Rudenok M.M.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Alieva A.Kh.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Karabanov A.V.

Research Center of Neurology

Illarioshkin S.N.

Research Center of Neurology

SPIN RSCI: 8646-9426
Scopus AuthorID: 7004025426
ResearcherID: C-9033-2012
ORCID: 0000-0002-2704-6282

Slominsky P.A.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Shadrina M.I.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Analysis of DNM2, EPN2 and EXOC4 relative gene expression levels in peripheral blood from Parkinson’s disease patients

Authors:

Semenova E.I., Rudenok M.M., Alieva A.Kh., Karabanov A.V., Illarioshkin S.N., Slominsky P.A., Shadrina M.I.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2021;39(3): 25‑30

DOI: 10.17116/molgen20213903125

Read: 984 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Semenova EI, Rudenok MM, Alieva AKh, Karabanov AV, Illarioshkin SN, Slominsky PA, Shadrina MI. Analysis of DNM2, EPN2 and EXOC4 relative gene expression levels in peripheral blood from Parkinson’s disease patients. Molecular Genetics, Microbiology and Virology. 2021;39(3):25‑30. (In Russ.)
https://doi.org/10.17116/molgen20213903125

Подписка 2026 Молекулярная генетика, микробиология и вирусология (Molecular Genetics, Microbiology and Virology)

Использование инфографики авторами научных работ

Close metadata

GOAL

Parkinson’s disease (PD) is a widespread disorder of the nervous system, which is associated with the degeneration of dopaminergic neurons in the substantia nigra. An important feature of PD is a long latency period of the disease. Hence, it is necessary to search for prognostic biomarkers. One of the methods for detecting PD biomarkers is the study of changes of gene expression in the peripheral blood from untreated patients with early stages of PD. To date, there is evidence that impaired membrane transport can play an important role in the pathogenesis of PD; therefore, in our work, we have analyzed changes in the relative mRNA levels of the DNM2, EPN2 and EXOC4 genes in the peripheral blood from treated and untreated patients with Parkinson’s disease.

MATERIAL AND METHODS

In the present work, 2 groups of patients with a diagnosis of Parkinson’s disease and 2 comparison groups were studied. Analysis of mRNA levels was performed using reverse transcription method and real-time PCR (TaqMan technology).

RESULTS

As a result of the work, no significant changes in the expression of the studied genes were found in the group of untreated PD patients. However, in the group of treated PD patients, we obtained statistically significant changes in the expression at the mRNA level for the DNM2 gene.

CONCLUSION

The results of our work suggest that genes DNM2, EPN2 and EXOC4 are not involved in the pathogenesis of the disease at the mRNA level in patients with early stage of PD. In this way, they cannot be used as prognostic biomarkers of PD. Changes in the expression of the DNM2 gene in treated PD patients suggest that this gene is involved in processes associated with dopamine agonist therapy.

Keywords:

Parkinson’s disease

gene expression

peripheral blood

Parkinson’s disease

gene expression

peripheral blood

Authors:

Semenova E.I.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Rudenok M.M.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Alieva A.Kh.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Karabanov A.V.

Research Center of Neurology

Illarioshkin S.N.

Research Center of Neurology

SPIN RSCI: 8646-9426
Scopus AuthorID: 7004025426
ResearcherID: C-9033-2012
ORCID: 0000-0002-2704-6282

Slominsky P.A.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Shadrina M.I.

The Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»

Received:

23.11.2020

Accepted:

30.03.2021

Close metadata

References:

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nature reviews Disease primers. 2017;3:17013. https://doi.org/10.1038/nrdp.2017.13
Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Frontiers in aging neuroscience. 2018;10:109. https://doi.org/10.3389/fnagi.2018.00109
Borrageiro G, Haylett W, Seedat S. A review of genome-wide transcriptomics studies in Parkinson’s disease. Eur J Neurosci. 2018;47(1):1-16. https://doi.org/10.1111/ejn.13760
Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain: a journal of neurology. 2009;132(Pt 7):1795-1809. https://doi.org/10.1093/brain/awn323
Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, Swaab DF, et al. Analysis of gene expression in Parkinson’s disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain pathology (Zurich, Switzerland). 2009;19(1):91-107. https://doi.org/10.1111/j.1750-3639.2008.00171.x
Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Nat Acad Sci USA. 2007;104(3):955-960. https://doi.org/10.1073/pnas.0610204104
Caronti B, Tanda G, Colosimo C, Ruggieri S, Calderaro C, Palladini G, et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson’s disease. Neuroreport. 1999;10(14):2907-2910. https://doi.org/10.1097/00001756-199909290-00006
Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B, et al. Increased expression of dopamine receptors on lymphocytes in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society. 1999;14(5):764-771. https://doi.org/10.1002/1531-8257(199909)14:5%3C764::aid-mds1008%3E3.0.co;2-w
Alieva AK, Filatova EV, Kolacheva AA, Rudenok MM, Slominsky PA, Ugrumov MV, et al. Transcriptome Profile Changes in Mice with MFTP-Induced Early Stages of Parkinson’s Disease. Molecular neurobiology. 2017;54(9):6775-6784. https://doi.org/10.1007/s12035-016-0190-y
Kalia LV, Lang AE. Parkinson’s disease. Lancet (London, England). 2015;386(9996):896-912. https://doi.org/10.1016/S0140-6736(14)61393-3
Hasegawa T, Sugeno N, Kikuchi A, Baba T, Aoki M. Membrane Trafficking Illuminates a Path to Parkinson’s Disease. The Tohoku journal of experimental medicine. 2017;242(1):63-76. https://doi.org/10.1620/tjem.242.63
Sheehan P, Yue Z. Deregulation of autophagy and vesicle trafficking in Parkinson’s disease. Neuroscience letters. 2019;697:59-65. https://doi.org/10.1016/j.neulet.2018.04.013
Alieva A, Shadrina MI, Filatova EV, Karabanov AV, Illarioshkin SN, Limborska SA, et al. Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson’s disease. BioMed research international. 2014;2014:718732. https://doi.org/10.1155/2014/718732
Starovatykh YS, Rudenok MM, Karabanov AV, Illarioshkin SN, Slominsky PA, Shadrina MI. Analysis of the expression of cln3, gabbr1 and wfs1 genes in patients with parkinson’s disease. Molecular Genetics Microbiology and Virology (Russian version). 2020;38(2):76. (In Russ.) https://doi.org/10.17116/molgen20203802176
Rudenok MM, Alieva AKh, Nikolaev MA, Kolacheva AA, Ugryumov MV, Pchelina SN i dr. Possible Involvement of Genes Related to Lysosomal Storage Disorders in the Pathogenesis of Parkinson’s Disease. Mol Biol. 2019;53(1):28-36. (In Russ.) https://doi.org/10.1134/S0026898419010142
Rosenthal JA, Chen H, Slepnev VI, Pellegrini L, Salcini AE, Di Fiore PP, et al. The epsins define a family of proteins that interact with components of the clathrin coat and contain a new protein module. J Biol Chem. 1999;274(48):33959-33965. https://doi.org/10.1074/jbc.274.48.33959
Munson M, Novick P. The exocyst defrocked, a framework of rods revealed. Nature structural & molecular biology. 2006;13(7):577-581. https://doi.org/10.1038/nsmb1097
Lalli G, Hall A. Ral GTPases regulate neurite branching through GAP-43 and the exocyst complex. J Cell Biol. 2005;171(5):857-869. https://doi.org/10.1083/jcb.200507061
Sans N, Prybylowski K, Petralia RS, Chang K, Wang YX, Racca C, et al. NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nature cell biology. 2003;5(6):520-530. https://doi.org/10.1038/ncb990
Kennedy MJ, Ehlers MD. Mechanisms and function of dendritic exocytosis. Neuron. 2011;69(5):856-875. https://doi.org/10.1016/j.neuron.2011.02.032
Mellone M, Zianni E, Stanic J, Campanelli F, Marino G, Ghiglieri V, et al. NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. Neurobiology of disease. 2019;121:338-349. https://doi.org/10.1016/j.nbd.2018.09.021
Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease. Journal of neurochemistry. 2010;114(2):499-511. https://doi.org/10.1111/j.1471-4159.2010.06776.x
Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism & related disorders. 2014;20(9):947-956. https://doi.org/10.1016/j.parkreldis.2014.05.003
Szénási G, Vegh M, Szabo G, Kertesz S, Kapus G, Albert M, et al. 2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochemistry international. 2008;52(1-2):166-183. https://doi.org/10.1016/j.neuint.2007.07.002
Grassart A, Cheng AT, Hong SH, Zhang F, Zenzer N, Feng Y, et al. Actin and dynamin2 dynamics and interplay during clathrin-mediated endocytosis. The Journal of cell biology. 2014;205(5):721-735. https://doi.org/10.1083/jcb.201403041
Koutsopoulos OS, Koch C, Tosch V, Böhm J, North KN, Laporte J. Mild functional differences of dynamin 2 mutations associated to centronuclear myopathy and Charcot-Marie Tooth peripheral neuropathy. PloS one. 2011;6(11):e27498. https://doi.org/10.1371/journal.pone.0027498
Stafa K, Tsika E, Moser R, Musso A, Glauser L, Jones A, et al. Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin GTPase superfamily. Human molecular genetics. 2014;23(8):2055-2077. https://doi.org/10.1093/hmg/ddt600
Ferguson SS, Zhang J, Barak LS, Caron MG. Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life sciences. 1998;62(17-18):1561-1565. https://doi.org/10.1016/S0024-3205(98)00107-6
Sander CY, Hooker JM, Catana C, Rosen BR, Mandeville JB. Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2016;41(5):1427-1436. https://doi.org/10.1038/npp.2015.296
Kabbani N, Jeromin A, Levenson R. Dynamin-2 associates with the dopamine receptor signalplex and regulates internalization of activated D2 receptors. Cellular signalling. 2004;16(4):497-503. https://doi.org/10.1016/j.cellsig.2003.09.011